Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript
Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.
How this was made
The 30-second read
Why it matters
The most tradable elements are (1) the magnitude of cash burn improvement and cash runway, and (2) the updated U.S. regulatory plan for DrugSorb-ATR after an FDA de novo denial, including scheduled late-August FDA pre-submission meetings.
Market read
CTSO’s call blends improving operating efficiency with continued regulatory and regional sales headwinds, making it a catalyst for probability shifts rather than a single binary outcome.
What to watch
Germany sales decline is attributed to headcount restrictions, so any delay in restoring territory coverage could extend the revenue drag even if U.S. regulatory progress improves.
Background
This is a Q2 2026 earnings call transcript covering financial performance, restructuring impacts, and regulatory/commercial updates for Cytosorbents’ investigational blood-filter devices.
Ticker impact
Cytosorbents reported Q2 2026 results and outlined FDA strategy for DrugSorb-ATR, including two late-August pre-submission meetings and a new de novo path after a denial.
Near-term volatility likely around FDA meeting expectations and any incremental clinical/regulatory details; fundamentals support a gradual re-rating if cash burn continues improving.
The call provides multiple concrete datapoints (revenue, margins, cash burn, FDA denial context, and scheduled FDA meetings) that can shift probability-weighting for U.S. approval timing, but it does not include an approval decision or new trial endpoint.
Market effects
Highlights ongoing regulatory and commercialization challenges for blood-purification and perioperative device developers, with FDA pathway execution as a key differentiator.
Germany restructuring and headcount limits are cited as a drag, implying near-term weakness in that geography until sales coverage is rebuilt.
Middle East distributor revenue is described as below expectations due to Iran-war disruptions, underscoring geopolitical sensitivity for medical device distribution.
Counterpoint
Despite improved gross margin and cash burn, the FDA de novo denial and missed STAR-T primary endpoint keep approval probability and timeline highly uncertain, which can cap upside.
Key entities
- companyCytosorbents Corporation
CTSO, reported Q2 2026 financials and discussed FDA pathway and commercial restructuring for DrugSorb-ATR and HemoDefend-BGA.
- product_programDrugSorb-ATR (STAR-T trial)
Investigational device program; FDA denied the original de novo application due to missed primary endpoint, prompting a new submission strategy.
- product_programHemoDefend-BGA
Gravity-driven filter program; management cited constructive FDA feedback and non-dilutive DoD/government funding to date.
- regulatorFDA
Referenced for de novo denial context and planned late-August pre-submission meetings to discuss additional data.
